WO2006081276A8 - 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity - Google Patents

3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity

Info

Publication number
WO2006081276A8
WO2006081276A8 PCT/US2006/002570 US2006002570W WO2006081276A8 WO 2006081276 A8 WO2006081276 A8 WO 2006081276A8 US 2006002570 W US2006002570 W US 2006002570W WO 2006081276 A8 WO2006081276 A8 WO 2006081276A8
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic
heteroaryl
hydroxy
amino
related compounds
Prior art date
Application number
PCT/US2006/002570
Other languages
French (fr)
Other versions
WO2006081276A1 (en
Inventor
Bertrand Leblond
Eric Beausoleil
Thierry Taverne
John E Donello
Original Assignee
Allergan Inc
Bertrand Leblond
Eric Beausoleil
Thierry Taverne
John E Donello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/814,601 priority Critical patent/US8013000B2/en
Application filed by Allergan Inc, Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E Donello filed Critical Allergan Inc
Priority to ES06719433.2T priority patent/ES2436612T3/en
Priority to BRPI0606112A priority patent/BRPI0606112B8/en
Priority to AU2006209208A priority patent/AU2006209208B2/en
Priority to CA002595542A priority patent/CA2595542A1/en
Priority to EP06719433.2A priority patent/EP1841742B1/en
Priority to JP2007553191A priority patent/JP5042040B2/en
Publication of WO2006081276A1 publication Critical patent/WO2006081276A1/en
Publication of WO2006081276A8 publication Critical patent/WO2006081276A8/en
Priority to US13/196,132 priority patent/US8513288B2/en
Priority to US13/834,336 priority patent/US8927589B2/en
Priority to US13/949,468 priority patent/US9399628B2/en
Priority to US14/954,263 priority patent/US9828349B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Compounds of the formula where the variables have the meaning defined in the specification have analgesic and or immunostimulant effect in mammals.
PCT/US2006/002570 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity WO2006081276A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP06719433.2A EP1841742B1 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
ES06719433.2T ES2436612T3 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propylamines and related compounds having analgesic and / or immunostimulant activity
BRPI0606112A BRPI0606112B8 (en) 2005-01-26 2006-01-25 3-hetero-aryl-3-hydroxy-2-amino-propyl amines and compounds related to analgesic activity, their use and pharmaceutical composition comprising them
AU2006209208A AU2006209208B2 (en) 2005-01-26 2006-01-25 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
CA002595542A CA2595542A1 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US11/814,601 US8013000B2 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity
JP2007553191A JP5042040B2 (en) 2005-01-26 2006-01-25 1-Aryl-1-hydroxy-2,3-diamino-propylamine, 1-heteroaryl-1-hydroxy-2,3-diamino-propylamine and related compounds having analgesic and / or immunostimulatory activity
US13/196,132 US8513288B2 (en) 2005-01-26 2011-08-02 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US13/834,336 US8927589B2 (en) 2005-01-26 2013-03-15 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity
US13/949,468 US9399628B2 (en) 2005-01-26 2013-07-24 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US14/954,263 US9828349B2 (en) 2005-01-26 2015-11-30 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64727105P 2005-01-26 2005-01-26
US60/647,271 2005-01-26

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/814,598 A-371-Of-International US8288556B2 (en) 2005-01-26 2006-01-25 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
US11/814,601 A-371-Of-International US8013000B2 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity
US13/196,132 Continuation US8513288B2 (en) 2005-01-26 2011-08-02 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US13/612,260 Continuation US8431599B2 (en) 2005-01-26 2012-09-12 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity

Publications (2)

Publication Number Publication Date
WO2006081276A1 WO2006081276A1 (en) 2006-08-03
WO2006081276A8 true WO2006081276A8 (en) 2007-05-03

Family

ID=36250723

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2006/002557 WO2006081273A1 (en) 2005-01-26 2006-01-25 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
PCT/US2006/002570 WO2006081276A1 (en) 2005-01-26 2006-01-25 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
PCT/US2006/002505 WO2006081252A2 (en) 2005-01-26 2006-01-25 Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
PCT/US2006/002580 WO2006081280A1 (en) 2005-01-26 2006-01-25 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002557 WO2006081273A1 (en) 2005-01-26 2006-01-25 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2006/002505 WO2006081252A2 (en) 2005-01-26 2006-01-25 Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
PCT/US2006/002580 WO2006081280A1 (en) 2005-01-26 2006-01-25 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity

Country Status (20)

Country Link
US (11) US8013000B2 (en)
EP (7) EP1841756B1 (en)
JP (6) JP5042040B2 (en)
KR (1) KR101395382B1 (en)
CN (2) CN102718748B (en)
AT (3) ATE549020T1 (en)
AU (4) AU2006209197A1 (en)
BR (5) BR122018068138B8 (en)
CA (4) CA2595544C (en)
DE (1) DE602006012801D1 (en)
DK (3) DK1841756T3 (en)
ES (5) ES2380904T3 (en)
HK (2) HK1145628A1 (en)
HU (1) HUE028654T2 (en)
MX (1) MX2007008955A (en)
NZ (1) NZ556614A (en)
PL (2) PL1841743T3 (en)
RU (1) RU2433999C2 (en)
WO (4) WO2006081273A1 (en)
ZA (1) ZA200706010B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
ES2380904T3 (en) * 2005-01-26 2012-05-21 Allergan, Inc. Pharmaceutical compositions that have an analgesic effect and contain 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
DK2032134T3 (en) 2006-05-09 2015-09-28 Genzyme Corp Processes for the treatment of fatty liver disease which includes inhibition of glucosphingolipidsyntese
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011485A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
TR201818771T4 (en) 2007-03-06 2019-01-21 Allergan Inc Compounds for Use in the Treatment of Cognitive Disorders
WO2008109285A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
CN101279955B (en) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 N-substituted thiamorpholine derivate as DPP-IV inhibitor and medical use thereof
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
RU2491931C2 (en) 2007-07-17 2013-09-10 Аллерган, Инк. Methods of treating anxiety
JP5896601B2 (en) 2007-10-05 2016-03-30 ジェンザイム コーポレーション Method for treating polycystic kidney disease using ceramide derivatives
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
RU2578947C2 (en) * 2008-10-03 2016-03-27 Джензайм Корпорейшн 2-acylaminopropanol glucosylceramide synthase inhibitors
AU2010273977A1 (en) 2009-07-17 2012-02-02 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
EP2477622B1 (en) 2009-09-16 2014-08-20 Allergan, Inc. Pharmaceutical composition for the treatment of spasticity
CA2774357A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating disorders of gastrointestinal motility
AU2010295703A1 (en) * 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating seizure disorders
CA2776849A1 (en) * 2009-11-18 2011-05-26 Fab Pharma S.A.S. Novel heterocyclic acrylamides and their use as pharmaceuticals
EP3033327B1 (en) 2013-08-15 2018-01-03 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use
CA2924545C (en) 2013-09-20 2022-12-06 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
JP6152816B2 (en) * 2014-03-26 2017-06-28 ソニー株式会社 SEMICONDUCTOR DEVICE, DISPLAY PANEL, DISPLAY DEVICE, ELECTRONIC DEVICE, AND SEMICONDUCTOR DEVICE MANUFACTURING METHOD
DE102015217629A1 (en) * 2015-09-15 2017-03-16 Tridonic Gmbh & Co Kg PFC module for intermittent operation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2514380A (en) * 1946-12-26 1950-07-11 Hoffmann La Roche Diamines and method of production
DE1001261C2 (en) 1954-08-05 1957-07-04 Thomae Gmbh Dr K Process for the preparation of basic esters of endocyclically substituted almond acids and their salts
US2918466A (en) 1955-05-24 1959-12-22 Univ St Johns Antimicrobial chemical compounds derived from alkoxyphenyl glycidic acid
US3065265A (en) 1957-07-04 1962-11-20 Hoffmann La Roche Amino acid hydrazides
SU1063026A1 (en) 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N-benzosulphonyl derivatives of treo-dl-phenylserine as antiinflammatory agent
EP0144290A3 (en) * 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituted ethylenediamine derivatives
JPS60132935A (en) 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd Phenylserine derivative and production thereof
JPS61145148A (en) 1984-12-19 1986-07-02 Sumitomo Seiyaku Kk Phenylseprine derivative
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
GB8622352D0 (en) * 1986-09-17 1986-10-22 Zambeleetti Spa Dr L Compounds
JPH02250845A (en) 1989-03-22 1990-10-08 Sumitomo Pharmaceut Co Ltd Production of 3-(4-fluorophenyl)propionaldehyde
DE69209576T4 (en) 1991-05-10 1997-01-30 Takeda Chemical Industries Ltd Pyridine derivatives, their production and use
JPH0550499A (en) 1991-08-27 1993-03-02 Kuwabara Yasunaga Trimming method in mold and container
US6696486B1 (en) 1992-01-22 2004-02-24 Glaxo Group Limited Medical use for atypical β-adrenoceptor agonists
DE69426331T2 (en) 1993-08-13 2001-06-21 Seikagaku Kogyo Co Ltd MEDICINE FOR NERVOUS DISEASES
JPH09506610A (en) 1993-12-17 1997-06-30 ディーエスエム エヌ．ブイ． Preparation of phenylserine amide and phenylserine / phenylserine amide
US5763438A (en) * 1994-06-10 1998-06-09 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
JPH10506531A (en) 1994-09-19 1998-06-30 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー Malaria Disease Treatment
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
FR2732894B1 (en) 1995-04-13 1997-07-04 Sanofi Sa NEW USE OF BETA9-ADRENERGIC AGONIST COMPOUNDS
JPH08337569A (en) * 1995-06-15 1996-12-24 Sankyo Co Ltd Analgesic active substance
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (en) * 1995-12-08 2007-10-17 生化学工業株式会社 Amino alcohol derivative and method for producing the derivative
NO965193L (en) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminal alcohol derivative and process for its preparation
DE19601745C1 (en) 1996-01-19 1997-10-09 Gruenenthal Gmbh Process for racemate resolution of tramadol
EP0848059A1 (en) 1996-12-12 1998-06-17 Vetigen Mammalian ICYP (Iodocyanopindolol) receptor and its applications
WO1998033501A1 (en) * 1997-01-31 1998-08-06 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
US6573387B1 (en) 1997-03-21 2003-06-03 The Scripps Research Institute Synthesis of α,β-substituted amino amides, esters, and acids
JP4036500B2 (en) * 1997-05-23 2008-01-23 生化学工業株式会社 Amino alcohol derivatives and pharmaceuticals containing the same
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
SE9904197D0 (en) 1999-11-22 1999-11-22 Amersham Pharm Biotech Ab An method for anion exchange adsorption on matrices carrying mixed mode ligands
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
WO2001047874A1 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
KR20000063913A (en) 2000-08-10 2000-11-06 하현준 Process for preparing 1,2-diaminopropane alcohols from aziridines
JP2004531478A (en) * 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Aminoceramide-like compounds and methods of use for therapeutic purposes
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
ATE555102T1 (en) 2001-07-16 2012-05-15 Genzyme Corp N-ACYLSPHINGOSINE LUCOSYLTRANSFERASE INHIBITOR
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
JP2006021997A (en) 2002-07-09 2006-01-26 Ono Pharmaceut Co Ltd cysLT1/cysLT2 BOTH RECEPTOR ANTAGONISTIC RESPIRATORY DISEASE-TREATING AGENT
JP2006510630A (en) 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド Phenylalanine derivatives as dipeptidyl peptidase inhibitors for treating or preventing diabetes
US20040229955A1 (en) 2003-01-08 2004-11-18 Andersen Niels H. Antibacterial agents
CA2548918C (en) 2003-12-11 2013-05-21 Mitsubishi Pharma Corporation Alpha-amino acid derivatives and use thereof as medicines
AU2004308966A1 (en) 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US20080221203A1 (en) 2004-08-09 2008-09-11 University Catholique De Louvain Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
DE102004053409A1 (en) 2004-11-05 2006-05-11 Bayer Healthcare Ag Process for the targeted production of lysobactin fragments
ES2380904T3 (en) * 2005-01-26 2012-05-21 Allergan, Inc. Pharmaceutical compositions that have an analgesic effect and contain 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
US7858825B2 (en) 2007-02-15 2010-12-28 Colorado State University Research Foundation Acid and base stable diphenylmethanol derivatives and methods of use
TR201818771T4 (en) * 2007-03-06 2019-01-21 Allergan Inc Compounds for Use in the Treatment of Cognitive Disorders
US20100105687A1 (en) * 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
WO2008109285A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
RU2491931C2 (en) * 2007-07-17 2013-09-10 Аллерган, Инк. Methods of treating anxiety
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
EP2285775B1 (en) * 2008-05-20 2017-03-22 Allergan, Inc. Lactams and their use in the treatment of inter alia ocular hypertension or baldness
EP2477622B1 (en) * 2009-09-16 2014-08-20 Allergan, Inc. Pharmaceutical composition for the treatment of spasticity
AU2010295703A1 (en) * 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating seizure disorders
CA2774357A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating disorders of gastrointestinal motility

Also Published As

Publication number Publication date
CN102718748A (en) 2012-10-10
AU2006209209B2 (en) 2012-07-19
BRPI0606112A2 (en) 2009-06-02
WO2006081273A1 (en) 2006-08-03
EP2489658A1 (en) 2012-08-22
ATE523491T1 (en) 2011-09-15
EP1841756B1 (en) 2011-09-07
EP1841742B1 (en) 2013-10-30
US20120225881A1 (en) 2012-09-06
EP1841743A1 (en) 2007-10-10
CA2595542A1 (en) 2006-08-03
US9828349B2 (en) 2017-11-28
EP2474534B1 (en) 2015-07-29
JP5107058B2 (en) 2012-12-26
ES2371265T3 (en) 2011-12-29
US20090036436A1 (en) 2009-02-05
AU2006209208B2 (en) 2012-08-23
BRPI0606111B1 (en) 2020-12-15
PL383715A1 (en) 2008-05-12
DE602006012801D1 (en) 2010-04-22
US8513288B2 (en) 2013-08-20
US20080312236A1 (en) 2008-12-18
HUE028654T2 (en) 2016-12-28
US20130202653A1 (en) 2013-08-08
HK1145628A1 (en) 2011-04-29
US8288556B2 (en) 2012-10-16
BRPI0606111A2 (en) 2009-06-02
CA2595522C (en) 2013-09-10
US20090088433A1 (en) 2009-04-02
AU2006209207B2 (en) 2012-08-23
US8153666B2 (en) 2012-04-10
JP2008528602A (en) 2008-07-31
CN101151248B (en) 2012-06-20
JP5042040B2 (en) 2012-10-03
BR122018068138B8 (en) 2022-02-08
US20090318499A1 (en) 2009-12-24
AU2006209208A1 (en) 2006-08-03
AU2006209207A1 (en) 2006-08-03
MX2007008955A (en) 2007-09-18
US20160083371A1 (en) 2016-03-24
JP5042039B2 (en) 2012-10-03
RU2433999C2 (en) 2011-11-20
NZ556614A (en) 2010-10-29
ES2565236T3 (en) 2016-04-01
ES2436612T3 (en) 2014-01-03
JP2008528601A (en) 2008-07-31
CA2595519C (en) 2013-10-29
US8013000B2 (en) 2011-09-06
HK1173721A1 (en) 2013-05-24
EP1841423A2 (en) 2007-10-10
CN102718748B (en) 2016-06-22
WO2006081276A1 (en) 2006-08-03
AU2006209207C1 (en) 2013-05-23
US8431599B2 (en) 2013-04-30
AU2006209209A1 (en) 2006-08-03
WO2006081273A8 (en) 2007-03-01
ES2340196T3 (en) 2010-05-31
JP2012162547A (en) 2012-08-30
BRPI0607379B8 (en) 2021-05-25
CA2595522A1 (en) 2006-08-03
ATE460159T1 (en) 2010-03-15
JP5039564B2 (en) 2012-10-03
US20130005717A1 (en) 2013-01-03
WO2006081252A3 (en) 2006-12-28
CA2595544C (en) 2013-04-02
US20120157497A1 (en) 2012-06-21
RU2007128313A (en) 2009-03-10
CA2595519A1 (en) 2006-08-03
EP1841743B1 (en) 2016-01-20
ES2380904T3 (en) 2012-05-21
BRPI0607379A2 (en) 2009-09-01
DK1841423T3 (en) 2010-06-07
DK1841756T3 (en) 2011-10-17
CA2595544A1 (en) 2006-08-03
US20130310383A1 (en) 2013-11-21
CN101151248A (en) 2008-03-26
EP2198864A1 (en) 2010-06-23
BRPI0607304A2 (en) 2009-08-25
US8835463B2 (en) 2014-09-16
EP1841742A1 (en) 2007-10-10
ZA200706010B (en) 2009-04-29
JP2008528596A (en) 2008-07-31
US9399628B2 (en) 2016-07-26
BRPI0606111B8 (en) 2021-05-25
EP1841423B1 (en) 2010-03-10
BRPI0607379B1 (en) 2020-06-30
EP2198864B1 (en) 2012-03-14
BRPI0606112B1 (en) 2021-02-23
US20110288094A1 (en) 2011-11-24
EP2489658B1 (en) 2014-04-09
KR101395382B1 (en) 2014-05-14
AU2006209197A1 (en) 2006-08-03
PL1841743T3 (en) 2016-06-30
US9278943B2 (en) 2016-03-08
KR20070098946A (en) 2007-10-05
JP2008528600A (en) 2008-07-31
BR122018068138B1 (en) 2021-09-08
WO2006081280A1 (en) 2006-08-03
JP2012162546A (en) 2012-08-30
EP2474534A1 (en) 2012-07-11
BRPI0606112B8 (en) 2021-05-25
ATE549020T1 (en) 2012-03-15
EP1841756A1 (en) 2007-10-10
DK1841743T3 (en) 2016-03-14
WO2006081252A2 (en) 2006-08-03
US8927589B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
WO2006081276A8 (en) 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
CY2018013I1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP2502938A3 (en) Antibodies and immunoconjugates and uses therefor
EP1835929B8 (en) Anti-kir combination treatments and methods
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2008054676A3 (en) Medical devices and methods of using the same
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2006050341A3 (en) Modified streptococcal polysaccharides and uses thereof
WO2006099232A3 (en) Antimicrobial pet wipes
WO2007059226A3 (en) Photoactivatable antimicrobial agents
WO2007075870A3 (en) Processes for taxane derivatives and intermediates useful therein
WO2006099219A3 (en) Absorbable surgical fasteners
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
EP1912630A4 (en) Compositions and methods for the reduction of post-operative pain
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
BRPI0722057A2 (en) COMPOUND, PRODUCT, PHARMACEUTICAL COMPOSITION, METHOD TO PREVENT OR TREAT SLEEP DISORDER, AND USE OF THE COMPOUND.
WO2007002842A3 (en) Substituted n-cinnamyl benzamides
ITBO20060289A1 (en) STACKING DEVICE FOR KIDSKINS, NAPKINS AND THE LIKE.
ITBO20050144A1 (en) HINGE FOR CABINETS AND THE LIKE
AU2004903861A0 (en) Inline and other fasteners
ES1055868Y (en) FURNITURE FOR RANGE OF AESTHETICS AND / OR ELECTROMEDICINE DEVICES.
ITBO20050056A1 (en) MODULAR STRUCTURE, PARTICULARLY FOR FURNISHINGS, EXHIBITORS, AND THE LIKE
ITMO20050169A1 (en) '' PANEL FOR FURNITURE OR SIMILAR ''.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2595542

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006209208

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006719433

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007553191

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006209208

Country of ref document: AU

Date of ref document: 20060125

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11814601

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0606112

Country of ref document: BR

Kind code of ref document: A2